Rhizen receives USFDA fast track designation for cancer drug
USFDA has granted Fast Track Designation for RP6530.. for the treatment of patients with relapsed/refractory peripheral T- cell lymphoma (PTCL)," Alembic Pharmaceuticals said in a BSE filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 11, 2017 Category: Pharmaceuticals Source Type: news
Mogamulizumab: Valuable New Option for Cutaneous Lymphoma Mogamulizumab: Valuable New Option for Cutaneous Lymphoma
An investigational monoclonal antibody directed against chemokine receptor 4 significantly improved progression-free survival in patients with cutaneous T-cell lymphoma.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Targeting cancer without destroying healthy T-cells
(Cardiff University) A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the aggressive and difficult-to-treat family of cancers, finds a study involving researchers from Cardiff University. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 15, 2017 Category: Cancer & Oncology Source Type: news
FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma
The drug had significant advantages over two other currently used agents in a phase 3 clinical trial.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Breast Implants Linked to Anaplastic Large-Cell Lymphoma
In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 24, 2017 Category: Cancer & Oncology Authors: Francisco Hernandez-Ilizaliturri, MD Scott Chapin, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Q T-Cell Lymphomas Source Type: news
BioCryst to receive royalties from cancer treatment approved in Japan
Durham-based BioCryst Pharmaceuticals (Nasdaq: BCRX) stands to receive royalties from a new cancer therapy approved in Japan.
The company announced that Mundipharma – with which it has a sub-licensing agreement – has received approval from the the Ministry of Health, Labor and Welfare in Japan for Mundesine, a therapy for the treatment of Peripheral T-Cell Lymphoma.
“Under the terms of the agreement with Mundiphar ma, BioCryst will receive tiered royalties ranging from the mid- to high-single… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 4, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news
Mundipharma ’s Mundesine receives approval from Japan’s MHLW to treat PTCL
Mundipharma has secured regulatory approval of Mundesine (Forodesine hydrochloride) from Japan ’s Ministry of Health, Labour and Welfare (MHLW) to treat relapsed / refractory Peripheral T-Cell Lymphoma (PTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 3, 2017 Category: Pharmaceuticals Source Type: news
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
RESEARCH TRIANGLE PARK, N.C., April 03, 2017 -- (Healthcare Sales & Marketing Network) -- BioCryst Pharmaceuticals, Inc. (BCRX) announced today that Mundipharma has obtained regulatory approval of Mundesine® (Forodesine hydrochloride) for the treatment... Biopharmaceuticals, Oncology, Regulatory BioCryst Pharmaceuticals, Mundesine, Forodesine, Peripheral T-Cell Lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2017 Category: Pharmaceuticals Source Type: news
FDA Warns of Rare Cancer Linked to Breast Implants
The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery. (Source: CancerNetwork)
Source: CancerNetwork - March 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Leukemia & Lymphoma News Source Type: news
MassDevice.com +5 | The top 5 medtech stories for March 22, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Japan clears Novocure’s 2nd gen Optune device
Novocure said today it won approval from the Japanese Ministry of Health, Labour and Welfare for its 2nd-gen Optune device.
The Optune is a mobile device that delivers low-intensi...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: MassDevice Tags: Blog News Well Plus 5 Source Type: news
FDA warns on lymphoma risk associated with breast implants
The FDA this month warned of an association between breast implants and the development anapestic large cell lymphoma.
The federal watchdog warned that the rare T-cell lymphoma can develop following implants, based on data the agency, and other health and regulatory bodies worldwide, have been collecting since 2011.
The exact number of cases “remains difficult to determine,” the FDA said, though data indicates that the occurrence of BIA-ALCL is more common following the implantation of breast implants with textured surfaces over those with smooth surfaces.
The FDA said it has received a total of 359 medical dev...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cosmetic/Aesthetic Food & Drug Administration (FDA) Women's Health Source Type: news
FDA Update on Rare Breast Implant-Associated Type of Lymphoma FDA Update on Rare Breast Implant-Associated Type of Lymphoma
The FDA says breast implant-associated anaplastic large cell lymphoma is a rare T cell lymphoma that can develop after breast implants and provides guidance for clinicians.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 21, 2017 Category: Cancer & Oncology Tags: Plastic Surgery & Aesthetic Medicine News Alert Source Type: news
EC grants marketing authorisation for Actelion ’s Ledaga to treat MF-CTCL
The European Commission (EC) has granted marketing authorisation for 160mcg of Actelion ’s Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news
New Therapies for T-Cell Lymphomas on the Horizon
There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/ICHM 2017 Leukemia & Lymphoma Source Type: news
